Back

Early therapy failure in incident pulmonary arterial hypertension

30 August 2026 (17:48 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy of pulmonary arterial hypertension Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Giulio Savonitto

Karolinska Institutet, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail
Dapagliflozin in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: the DAPAH randomized controlled trial
Doctor M. Ersboll (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Efficacy and safety of treprostinil in pulmonary arterial hypertension: a meta-analysis of randomized trials
Doctor M. Malik (Lahore, Punjab, PK)
Abstract Slides
Presentation thumbnail
Quick and sustained right ventricular reverse remodeling at early, mid and late follow-Up under sotatercept
Doctor M. EL BLIDI (Le Kremlin-Bicetre, FR)
Abstract Slides
Presentation thumbnail
Impact of targeted therapies withPDE5 inhibitors, endothelin receptor antagonists and sotatercept on functional tricuspid regurgitation in pulmonary arterial hypertension
Mr J. Gentz (Cologne, DE)
Abstract Slides

Access the full session

Session thumbnail
Pharmacotherapy of pulmonary arterial hypertension
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 17:48 CET
You may be interested in
thumbnail
Congress Presentation
Early treatment failure in incident pulmonary arterial hypertension
13 May 2024
thumbnail
Congress Presentation
Pulmonary hypertension in heart failure with preserved ejection fraction: the TOPCAT Americas and PARAGON-HF studies
29 June 2021
thumbnail
Congress Presentation
Poor outcomes in pulmonary arterial hypertension as a member of RNF213-associated vascular diseases
3 September 2019
thumbnail
Congress Presentation
Identification of predictors of response to initial oral combination therapy in WHO-functional class II or III PAH patients: A post-hoc analysis of the AMBITION study
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources